THANK YOU FOR SUBSCRIBING
Continuous manufacturing solutions with advanced cloud computing and automation systems create opportunities for pharmaceutical companies using advanced manufacturing technologies.
FREMONT, CA: Despite prolonged shutdowns of many chemical and pharmaceutical manufacturing plants and a gradual restoration to production after lockdowns were lifted and factories could resume, the pharmaceutical supply chain has shown to be quite durable, at least during the first few months of the pandemic. Even though there were challenges, most originated from local procurement constraints instead of a lack of access to critical raw materials, intermediates, or active pharmaceutical ingredients (APIs) from distant vendors.
Several businesses responded quickly, applying safety rules and devising solutions that allowed operators to stay at work or return after few weeks of quarantine. For to the critical nature of these processes, shutdowns for the production of life-saving drugs were restricted. Many businesses also have substantial product stocks to ensure continuous delivery.
In recent years, several contract manufacturers and their clients have focused on integrating pharmaceutical supply chains and establishing dual sourcing for essential ingredients. Many facilities in various nations that cannot withstand the obstacles posed by the COVID-19 pandemic have already been closed due to many governments' recent push to terminate firms that fail to achieve environmental and quality performance standards.
Glocalization Equals Localization
But the pandemic had boosted the glocalization movement, which was already encouraging a rise in local production in many nations before COVID-19 emerged. Major pharmaceutical corporations have set up production facilities in various locales, either directly or through partnerships with local businesses or contract service providers. Domestic producers have extended their position in most emerging regions.
Enhanced outsourcing to contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs), the introduction of modular manufacturing solutions, and the increasing adoption of flow chemistry or continuous processing have all aided glocalization in the pharmaceutical industry.
Outsourcing gives pharma companies access to specialized technologies and might help save money by increasing efficacy and productivity. It is a primary business approach for small or rising businesses that frequently use a virtual manufacturing model. Outsourcing allows every drug developer to have a footprint in countries where local production is required. CDMOs or CROs with global networks provide dual or multiple sourcing solutions. To meet regulatory requirements for LPP, modular and flexible manufacturing solutions allow the replication of small production facilities in many areas.
Sophisticated manufacturing technologies paired with continuous manufacturing solutions and highly advanced cloud computing and automation systems allow for cost-efficient in-country medication production.